Interrupting antiretroviral treatment in HIV cure research: scientific and ethical considerations
Samual Garner(Washington University in St. Louis), Liza Dawson(National Institute of Allergy and Infectious Diseases), Adam Gilbertson(University of North Carolina at Chapel Hill), Stuart Rennie(University of North Carolina at Chapel Hill), Jintanat Ananworanich(Henry M. Jackson Foundation), Jeremy Sugarman(Johns Hopkins Berman Institute of Bioethics), David M. Margolis(University of North Carolina at Chapel Hill), Randall Tressler(National Institute of Allergy and Infectious Diseases), Karine Dubé(University of North Carolina at Chapel Hill)
Cited by 55
Related Papers
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
|Nature|2012|1.2k
The Challenge of Finding a Cure for HIV Infection
|Science|2009|850
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
|New England Journal of Medicine|2021|847
Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021
|Nature Medicine|2021|367
Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus–Infected Donors to Noninfected Recipients
|Annals of Internal Medicine|2018|295